Related by context. All words. (Click for frequent words.) 82 Reports Positive 81 Announces Positive 81 Receives Favorable 78 Announces Initiation 78 Announces Favorable 78 Updates Status 76 Announces Successful Completion 76 Presents Positive 76 Submits Application 76 Announces Preliminary 75 Provides Update Regarding 75 Confirms Receipt 75 Updates Shareholders 75 Announces Commencement 75 Completes Enrollment 75 Provides Guidance 75 Receives Conditional 75 Provides Updates 75 Significantly Increases 75 Completes Initial 75 Reveals Positive 75 FDA Clears 75 Commences Phase 75 Receives Milestone Payment 74 Announce Collaboration Agreement 74 Announces Publication 74 Receives Patent 74 Provides Preliminary 74 Obtains Approval 74 Reconfirms 74 Provides Clarification 74 Receives Orphan Drug Designation 74 Files IND 74 Finalizes Acquisition 74 Sign Licensing Agreement 74 Jointly Announce 74 Successfully Completed 74 Completes Patient Enrollment 74 Provides Update 74 Discontinues 74 Announces Termination 74 Receives Approval 74 Receives Conditional Approval 74 Announce Completion 74 Provides Updated 74 Receives Notification 74 Achieves Significant 74 Receives Regulatory 74 Sign License Agreement 73 Confirms Significant 73 Cites Positive 73 Summarizes 73 Achieves Positive 73 Results Confirm 73 Successfully Completes 73 Demonstrates Positive 73 Announces Successful 73 Announces FDA Clearance 73 Adopts Shareholder Rights 73 Significantly Improves 73 Announces Licensing Agreement 73 Closes Acquisition 73 Releases Third Quarter 73 Announces Revised 73 Significantly Expands 73 Attains 73 Receives Clearance 73 Completes Financing 73 Rated Speculative Buy 73 Amends Agreement 73 Receives Favorable Ruling 73 Positive Results 73 Closes Financing 73 Jumps Higher 73 Announces Non Brokered 72 Q3 Loss Narrows 72 Finalizes Agreement 72 Signs Option Agreement 72 Initiates Phase II 72 Formalizes 72 Significantly Reduces 72 Submits NDA 72 Achieves Milestone 72 Enrolls First 72 Strengthens Its 72 Q3 Loss Widens 72 Announces Issuance 72 Receives Approvable Letter 72 Receives Certification 72 Awarded Patent 72 Receives FDA Clearance 72 Board Unanimously Rejects 72 Q4 Loss Narrows 72 Introduces Enhanced 72 Receives Notice 72 FDA Accepts 72 Study Confirms 72 Announces Granting 72 Receives Unsolicited 72 Acquire Assets 72 Subsidiary Acquires 72 Presents Preclinical Data 72 Announce Receipt 72 Announces Presentation 72 Announce Merger Agreement 72 Receives Complete Response 72 Reports Receipt 72 Announces Stockholder Approval 72 Seeks Approval 72 Releases Latest 72 Announces Immediate Availability 72 Releases Second Quarter 72 Validates 72 Announce License Agreement 72 Shows Promise 72 Aquires 72 Study Demonstrates 72 Issues Statement Regarding 72 Issues Clarification 72 Announces Receipt 72 Shareholders Approve Acquisition 72 Settle Patent Litigation 72 Announces Dismissal 72 Significant Increase 72 Exercises Option 72 Initiates Phase III 72 Provides Shareholder 71 Subsidiary Enters 71 Engages Investor Relations 71 Launches Enhanced 71 Q2 Loss Narrows 71 Enters Agreement 71 Announce Settlement 71 Q4 Loss Widens 71 Resubmits 71 Retains Investor Relations 71 Regains Compliance 71 Completes Purchase 71 Files Shelf Registration Statement 71 Announces Signing 71 Announces Expanded 71 Licenses Novel 71 Initiates Clinical Trial 71 Secures Financing 71 Receives Orphan Drug 71 Announces Formation 71 Provides Operational Update 71 Sees Positive 71 Announces Shareholder Approval 71 Issues Guidance 71 Joins OTCQX 71 Identifies Potential 71 Terminates Contract 71 Maintains Strong 71 Provide Comprehensive 71 Receives NASDAQ 71 Acquires Controlling Interest 71 Announces Divestiture 71 Acquires Assets 71 Completes Successful 71 Demonstrates Significant 71 Releases Next Generation 71 Sinks Lower 71 Streamlines Operations 71 Announces Acquisition 71 Enters Into Definitive Agreement 71 Announces Filing 71 Q1 Loss Narrows 71 Closes Previously Announced 71 Announces Tentative Approval 71 Announces Availability 71 Initiates Dosing 71 Announces Completion 71 Consummates 71 Achieves Record Sales 71 Announces Enhancements 71 Sign Definitive Agreement 71 Finalizes Purchase 71 Temporarily Suspends 71 Regains Compliance With 71 Files Patent Application 71 Provides Comprehensive 71 Reminds Shareholders 71 Q2 Loss Widens 71 Coverage Initiated 71 Announce Licensing Agreement 71 Announce Merger 71 Shareholders Approve Merger 71 Receives Confirmation 71 Receives Positive Results 71 Initiates Clinical Trials 71 Announce Commencement 71 Stockholders Approve Acquisition 70 Net Loss Narrows 70 Delivers Strong 70 Pending Acquisition 70 Files NI #-# 70 Changes Name 70 Completes Acquisition 70 Closes Private Placement 70 Announces Additions 70 Closes Second Tranche 70 Net Loss Widens 70 Shares Soar 70 Board Authorizes 70 Announces Proposed 70 Drug Candidate 70 Completes Merger 70 Grants Options 70 Successfully Complete 70 Reaffirms Commitment 70 Shows Promising 70 Completes Private Placement 70 Announces Adjournment 70 Announces Early Termination 70 Presents Positive Preclinical 70 Files Patent 70 Announces Postponement 70 Announces Effective Date 70 Planned Acquisition 70 Renegotiates 70 BioSante Pharmaceuticals Announces 70 Initiates Enrollment 70 Completes Merger With 70 Increases Ownership 70 Spins Out 70 Subsidiary Receives 70 Receives Positive Opinion 70 Extends Collaboration 70 Signs License Agreement 70 Q1 Loss Widens 70 Broadens Its 70 Further Strengthens 70 Introduces Next Generation 70 Begins Dosing 70 Terminate Merger Agreement 70 Submits Biologics License Application 70 Receives Approval From 70 IIROC Resume 70 Recommends Approval 70 Exceeds Expectations 70 Wins Approval 70 Confirms Commitment 70 Completes Acquisitions 70 Expand Relationship 70 Drilling Underway 70 Strengthens Position 70 Explore Strategic Alternatives 70 Reacquires 70 Successfully Closes 70 Announces Definitive Agreement 70 Initiates Clinical 70 Acquires Exclusive 70 Clarifies Status 70 Shareholders Approve 70 IIROC Halt 70 Announces Private Placement 70 Publishes Updated 70 Unveils Latest 70 Settle Patent Dispute 70 Gets Favorable 70 Successfully Concludes 70 Posts Strong 70 Terminates Agreement 70 Reduces Risk 70 Report Indicates 70 Submits 70 Launches Next Generation 70 Expand Collaboration 70 Flamel Technologies Announces 69 Begins Drilling 69 Amend Merger Agreement 69 Unveils Expanded 69 Clinical Trial Results 69 Receives CE Marking 69 Spins Off 69 Introduces Expanded 69 Initiates 69 Announces Cancellation 69 Obtains 69 Quadruples 69 Approve Merger 69 Signs Licensing Agreement 69 Completes Transition 69 Monetizes 69 Announces Addition 69 Enters Into Agreement 69 Gets FDA Clearance 69 Secures Funding 69 Strengthens Leadership 69 Finalizes 69 Identifies Key 69 Strengthens Balance Sheet 69 Announce Early Termination 69 Announce Availability 69 Stockholders Approve Merger 69 Completes Expansion 69 TSX Delisting 69 Collaborators Present 69 Amends Terms 69 Announces Discontinuation 69 Present Preclinical Data 69 Secures Additional 69 Appoints Seasoned 69 Receives Tentative Approval 69 Initiating Coverage 69 Regains Full 69 Reports Profitable 69 Fortifies 69 Affirms Commitment 69 Increases Size 69 Closes Sale 69 Q1 Adj 69 Enters Into Strategic 69 Announces Stock Repurchase 69 Moves Towards 69 Provides Detailed 69 Regains NASDAQ 69 Achieves Record 69 Voluntarily Withdraw 69 Appoints Experienced 69 Gets Approval 69 Jointly Develop 69 Files Amended 69 FDA Okays 69 Announces License Agreement 69 Announce Expiration 69 Shareholder Opinions 69 Introduces Breakthrough 69 Submits IND 69 Improves Survival 69 Completes Previously Announced 69 BayStreet.ca Research Alert 69 Expands Scope 69 Announces Expansion 69 Outperforms 69 &Amp; 69 Announces Organizational Changes 69 Anounces 69 Annouces 69 Bolsters 69 Granted Orphan Drug 69 Boosts Productivity 69 Updates Guidance 69 Patent Infringement Lawsuit 69 Phase 2b Clinical Trial 69 Stockholders Approve 69 Enter Into 69 Initiates Phase 69 Receives Highest 69 Completes Tender Offer 69 Retains Leading 69 Restate Financial 69 Patient Enrollment 69 Extends Expiration Date 69 Receives Recognition 69 More Than Doubles 69 Files Restated 69 Therapeutic Competitors Companies 69 Signs Definitive 69 Announce Collaboration 69 Signs Agreements 69 Closes Acquisition Of 69 Study Indicates 69 Immunomedics Announces 69 Reinforces 68 Commercializes 68 Results Indicate 68 Announces Intention 68 Introduces Unique 68 Completes Integration 68 Licenses Patents 68 Acquirer Company 68 Significantly Improved 68 Announce Expanded 68 Taglich Brothers Initiates Coverage 68 TSX Delisting Review 68 Mobilizes 68 Executes Agreement 68 Tops Q4 68 Announces Debt Settlement 68 Pinnacle Digest Looking 68 Receives Prestigious 68 StockPreacher.com Issues Trading 68 Revises Fourth Quarter 68 Drug Fails 68 Enters Into Letter 68 Nears Completion 68 Introduces Revolutionary 68 Obtains FDA 68 FY# Loss Widens 68 Phase III Clinical Trial 68 News Unternehmensnachrichten 68 Updates Outlooks 68 Commences 68 Achieves Record Revenue 68 Shares Surge 68 Reports Assay Results 68 Shares Plummet 68 Taro Receives 68 Sees Continued 68 Misses Q1 68 CRWESelect CRWESelect.com Highlights 68 Announces Profitable 68 Receives Fast Track 68 Completes Divestiture 68 Drilling Completed 68 Commences Phase III 68 Subsidiary Signs 68 Expects Higher 68 Submits Supplemental 68 Launches Innovative 68 FDA Approves 68 Lowers Guidance 68 Complete Merger 68 Unsolicited Proposal From 68 Awarded Patents 68 Announces Share Repurchase 68 Meets Primary Endpoint 68 Finalizes Sale 68 Jointly Offer 68 Releases Enhanced 68 Teva Provides Update 68 Successfully Tests 68 Successfully Completes Tender Offer 68 Generates Record 68 Modifies 68 Revises Third Quarter 68 Achieves Highest 68 Initiate Phase III 68 Launches Unique 68 Commence Drilling 68 Study Validates 68 Delays Filing 68 Settles Litigation 68 Record Third Quarter 68 Drilling Intersects 68 Extends Reach 68 DayTradersDigest.com Profiles 68 Canaccord Genuity Reiterates Buy 68 Above Estimates 68 Resumes Drilling 68 Unveils Revolutionary 68 Commences Drilling 68 Extends Tender Offer 68 Receives Commitment 68 Daytradersdigest.com 68 Osteoporosis Drug 68 Delineates 68 Recieves 68 Enlarges 68 Q2 Profit Declines 68 FDA Approvals 68 Files Definitive Proxy 68 Posts Wider Loss 68 Inks Pact 68 Further Validates 68 Completes Drilling 68 Wins Patent Infringement 68 NDA Submission 68 Wins Prestigious 68 Announces Record Date 68 Preliminary Injunction Against 68 CFO Resigns 68 Realigns 68 Engages 68 Enters Into Exclusive 68 Pharmaceuticals Initiates 67 Files Revised 67 Initiates Phase 2b 67 Receives Anticipated 67 Guides Inline 67 Expands Capabilities 67 Unveils Next Generation 67 Enters Into License Agreement 67 Successfully Completes Phase 67 Settle Litigation 67 Inc. Nasdaq OXGN 67 Announces Favorable Ruling 67 Develop Novel 67 Repositions 67 Acquire Controlling Stake 67 Completes Purchase Of 67 Cuts FY# 67 Clears Path 67 Reclassifies 67 Q4 Profit Plunges 67 Patent Infringement Litigation 67 Ink Deal 67 Collaborates With 67 Expands Scientific Advisory 67 Univest Corporation Declares 67 Successfully Completes Acquisition 67 Demonstrates Commitment 67 Data Suggest 67 Drilling Extends 67 Lowers Q4 67 Reports Significantly Improved 67 Unanimously Recommends 67 Accelerates Growth 67 Closes Non Brokered 67 Files Investigational 67 Completes Sale 67 Gains Ground 67 Announces Intent 67 Commences Exploration 67 Concludes Successful 67 Announces Reverse Split 67 Q4 Profit Surges 67 Restates 67 Achieves Unprecedented 67 Furthers 67 Announces Departure 67 Patent Issued 67 Retracts 67 Lupus Drug 67 Phase IIb Trial 67 Wins Coveted 67 Closes Merger 67 Announce Successful Completion 67 Announces Restatement 67 Completes Reverse Merger 67 Completes Transaction 67 Announces Launch 67 Receives Approvals 67 Announces Resignation 67 Q3 Profit Surges 67 Announces Proposed Acquisition 67 Announce Agreement 67 Dramatically Increases 67 Flagship Product 67 Announces Upcoming 67 Lowers 4Q 67 Penetrates 67 Moves Forward 67 Forecast Quick Facts 67 Terminates 67 Announcement Regarding 67 Improves Outcomes 67 Buy Privately Held 67 Confirms Efficacy 67 Earns Highest 67 Stays Neutral 67 Completes Due Diligence 67 Delivers Comprehensive 67 Achieves Record Growth 67 Finalises 67 Expands Portfolio 67 Extends Offer 67 Withdraws Proposal 67 Expert Joins 67 Unveils Innovative 67 Expands Distribution 67 Arthritis Drug 67 Successful Completion 67 Revolutionizes 67 Q1 Profit Declines 67 Mails Offer 67 Single Dose 67 Study Proves 67 Revises Guidance 67 Announce Formation 67 Starts Drilling 67 Publishes 67 Enters Strategic 67 Receives CE 67 Acquires Remaining Interest 67 Reduces Debt 67 Named Fastest Growing 67 Announce Initiation 67 Approves Merger 67 Q2 Profit Rises 67 CRWEWallstreet.com Stock Report 67 Increases Stake 67 Guides Below 67 Achieves ISO #:# Certification [002] 67 Refines 67 Begins Shipment 67 Announce Filing 67 Enters Joint Venture 67 Files Voluntary 67 Completes Restructuring 67 Report Examines 67 Has Commenced 67 Posts Record 67 Formally Launches 67 Announce Strategic 67 ISS Recommends 67 Patent Lawsuit 67 Announces Sponsorship 67 Confirms 67 Receives Prestigious Award 67 Patent Dispute 67 Achieves Certification 67 Enters Negotiations 67 Trial Evaluating 67 Momentum Continues 67 Reaffirms 67 Achieves Profitability 67 Review Initiated 67 Undertakes 67 LLP Investigating 67 Announce Shareholder Approval 67 Begins Shipping 67 Q1 Profit Surges 67 CybeRelease Decliners 67 Announces Mailing 67 Smartstox.com Spotlights 67 Amplifies 67 Receives Stockholder Approval 67 Deliver Integrated 67 Statement Regarding 67 Earnings Postmortem 67 Commences Trading 67 Delivers Next Generation 67 Subsidiary Expands 67 Alert Technicals Showing Bearish 67 Disappoints 66 Inks Deal With 66 Q2 Profit Surges 66 Presents Preclinical 66 Progresses 66 Helps Reduce 66 Receives Permit 66 Satisfies 66 Announce Licensing 66 Announces 66 Debuts Next Generation 66 Q4 Profit Rises 66 Bodes Well 66 Elevates 66 Favorable Ruling 66 Positions Itself 66 Expands Reach 66 Proudly Announces 66 Files Lawsuit Against 66 Sets Record Date 66 Receives Authorization 66 Sign Definitive Merger 66 Completes Buyout 66 Completes Conversion 66 Conference Call TRANSCRIPT 66 Cuts Costs 66 AllPennyStocks.com Spotlights 66 Obtains Extension 66 Announce Signing 66 Signs Binding Letter 66 Solidifies 66 Revenues Decline 66 Receives Shareholder Approval 66 FDA Panel Recommends 66 Expands Deployment 66 Announce Exclusive 66 Commences Operations 66 Gets Mixed Reviews 66 Study Evaluating 66 Forges Ahead 66 Announce Joint Venture 66 Arranges Private Placement 66 Given Outperform Rating 66 Discloses 66 Demands Immediate 66 Substantially Increases 66 Engages CHF Investor Relations 66 Files Preliminary Prospectus 66 Exercises Warrants 66 PPD Declares 66 Q2 Adj 66 Buys Majority Stake 66 Significantly Expand 66 STERIS Corporation Announces 66 Magazine Recognizes 66 Remains Neutral 66 Gout Drug 66 Introduces Powerful 66 Expands Into 66 Trading Halt 66 Reports Fiscal 66 Outlines Strategy 66 Has Received 66 Misses Q4 66 Q3 Profit Rises 66 Demonstrates Long Term 66 Beefs Up 66 Record Fourth Quarter 66 Verifies 66 Reach Settlement 66 Shareholders Approve Sale 66 Reaches Milestone 66 Guides Above 66 Launches Breakthrough 66 Identifies Significant 66 Files Shelf Registration 66 Completes Patient Enrolment 66 Receives Subpoena 66 Sees Strong 66 Seek Shareholder Approval 66 Regains Nasdaq 66 Enters Into Joint Venture 66 Signs Definitive Agreement 66 OTCStockExchange.com Stock Alert 66 Enters Into 66 please visit http:/www.stockguru.com 66 Halts Production 66 Reorganizes 66 Q1 Profit Rises 66 Re Affirms 66 TriCo Bancshares Announces 66 Completes Recapitalization 66 Prolongs 66 1st Writethru 66 Recommences 66 Completes Second Tranche 66 Attains Gold Certified Partner 66 Continues Expansion 66 Commences Drill Program 66 Settles Patent Litigation 66 Enters Into Definitive 66 Adopts Stockholder Rights 66 Unsolicited Tender Offer 66 Officially Launches 66 www.otc advisors.com names 66 Reach Settlement Agreement 66 Commence Phase 66 Announces Operational Update 66 Revises 66 Receives Funding 66 4Q Loss Widens 66 Receives Order 66 Revises Q4 66 Q4 Profit Declines 66 Signs Purchase Agreement 66 Reactivates 66 Continues Momentum 66 Receives 66 Winning Streak Continues 66 Commences Drilling Program 66 Holds Annual Meeting 66 Reports Third Quarter 66 Settles Dispute 66 Certifies 66 Q3 Profit Declines 66 Delivers Unprecedented 66 Private Placement Closed 66 Announces Affiliation 66 Sees Significant 66 Achieves SAS 66 Patent Infringement Lawsuit Against 66 Files Registration Statement 66 Earns Top 66 Acknowledges Receipt 66 Widens Quick Facts 66 Alert Technicals Showing Bullish 66 Commences Initial 66 Helps Improve 66 Completes Sale Of 66 Signs MOU 66 Investigational Compound 66 Gains Momentum 66 Submits Response 66 XPEL Announces 66 Welcomes Analyst Initiation 66 Evaluate Strategic Alternatives 66 Restructures Debt 66 Announces Appointment 66 Extend Partnership 66 Mylan Receives Approval 66 Amends Private Placement 66 Thewallstreetleader.com Profiles 66 Launches Groundbreaking 66 Delivers Powerful 66 Completes Installation 66 Introduces Innovative 66 Phase III Trial 66 Crowflight Announces 66 Withdraws Application 66 Releases Findings 66 Posts Quarterly 66 Releases Latest Version 66 Announces Normal Course 66 Achieves Record Quarterly 66 Commence Trading 66 BIOLASE Announces 66 Restructures 66 Subsidiary Completes 66 Reiterates Fiscal 66 Celebrates Successful 66 Combination REOLYSIN R 66 Accepted Into 66 Gets Boost 66 otcstockexchange.com 66 Subsidiary Enters Into 66 Enhances User Experience 66 Below Consensus 66 Submits Revised 66 Builds Momentum 66 Earns Milestone Payment 66 Sees Continued Growth 66 Signs Lease 66 Unveils Newest 66 Clarifies Position 66 Snaps Up 66 Introduces Novel 66 Announces Recapitalization 66 Refocuses 66 Doubles Capacity 66 Extends Maturity 66 Launches Generic Version 66 Signs Agreement 66 Obtains Exclusive License 66 Announces Closing 66 Study Identifies 66 Delivers Breakthrough 66 Previously Announced 66 Broadens 66 Reaches Agreement 66 Pivotal Phase III 65 Reports Second Quarter 65 Bulks Up 65 Unveils Enhanced 65 Provides Operational 65 Signs LOI 65 Announce Launch 65 Completes Asset 65 Obtains License 65 Review Strategic Alternatives 65 Terminates Merger Agreement 65 Initiate Clinical Trial 65 Dramatically Improves 65 Preliminary Third Quarter 65 Rejects Unsolicited 65 Shareholders Approve Merger Agreement 65 Signs Long Term 65 Resubmit 65 Initiates Voluntary Recall 65 Successfully Integrates 65 Oral Calcitonin 65 Receives Notice From 65 Nearly Triples 65 Proves Successful 65 Executes Letter 65 Bearish Speculation 65 Announces Release Date 65 Taps Into 65 Announces Resumption 65 Patent Upheld 65 Successfully Launches 65 Stock Upgraded 65 Assets Acquirer Company 65 Initiates Coverage 65 Rebrands 65 Up Sharply 65 Sweetens Bid 65 Deepens 65 Announces Dosing 65 Receives Permission 65 Accelerates 65 Forms Strategic 65 Delivers Solid 65 Narrows Guidance 65 Plummets 65 Wolf Haldenstein Investigating 65 Sees Higher 65 Shareholders Approve Arrangement 65 L.P. Announces 65 Phase IIa Clinical Trial 65 Announces Cash Dividend 65 Recertified 65 VIVUS Announces 65 Acquire Controlling Interest 65 Scoops Up 65 Preclinical Data 65 Ceases 65 Issued Patent 65 Shares Climb 65 Rises Quick Facts 65 Draws Attention Of 65 3rd Quarter Results 65 Provides Status 65 Launches Redesigned 65 Announces Definitive Merger 65 Present Webinar 65 Analyst Upgrade 65 Announces Refinancing 65 Expands Capacity 65 Relaunches 65 Demonstrates Potential 65 Releases Statement Regarding 65 Adopts 65 Outshines 65 Settle Dispute Over 65 Resolves Dispute 65 Successfully Deploys 65 Signs Joint Venture 65 Receives Highest Rating 65 Receives Coveted 65 :/ finance.yahoo.com q 65 Vigorously Defend 65 Schedules Second Quarter 65 Acquire Remaining 65 Posts Solid 65 Acquires 65 Extends Relationship 65 Expands 65 Withdraws 65 Achieves ISO # 65 Record Second Quarter 65 Files Formal 65 Bullish Speculation 65 Media NewsEdge STOCK MARKETING 65 Psoriasis Drug 65 Announces Rebranding 65 Higher Than Expected 65 Gets Clearance 65 Initiates Drilling 65 Makes Strides 65 Acquisition Strengthens 65 Directors Unanimously Rejects 65 Awarded Prestigious 65 Lowers Price 65 Develop Next Generation 65 Phase IIb Clinical Trial 65 Voluntarily Withdraws 65 Expands Coverage 65 Launches Redesigned Website 65 Completes Reorganization 65 Enters Option Agreement 65 Withdraws Offer 65 Drilling Commences 65 Offers Unique 65 Posts Narrower Loss 65 Obtains Exclusive Rights 65 Subsidiary Wins 65 Prostate Cancer Vaccine 65 Revenues Increase 65 Protects Against 65 Dramatically Expands 65 Licensing Pact 65 Appoints 65 Obtains Patent 65 Report Analyzes 65 Reaffirms FY# EPS 65 Speeds Up 65 Report Initiates Independent 65 TheWallStreetLeader.com Profiles 65 Posts Higher 65 Guides Q2 65 FY# Loss Narrows 65 Moves Ahead 65 Signs Letter 65 Stock Soars 65 Announces Second Quarter 65 Enters Into Licensing Agreement 65 Hits Milestone 65 Skymark Research Initiates Independent 65 Study Examines 65 Completes Redemption 65 Calls Purchased 65 Being Evaluated 65 Markettelegraph.com 65 Updates Fourth Quarter 65 Infringes 65 Develops Novel 65 Schedules Third Quarter 65 Reaffirms Outlook 65 Experiences Significant 65 Announces Quarterly 65 Terminate Agreement 65 Regains 65 Develops Innovative 65 Edges Up 65 1st Quarter Results 65 Completes 65 Amends Credit 65 Beats Zacks 65 Outlook Quick Facts 65 Demonstrates Statistically Significant 65 Reduces Workforce 65 Shareholders Reject 65 Raises Guidance 65 Medoro Resources Announces 65 Latest Addition 65 Signs Reseller Agreement 65 Newly Acquired 65 Below Estimates 65 Stock Downgraded 65 Reiterates Buy 65 Options Activity 65 Unveils Breakthrough 65 Gaining Traction 65 Announces Expiration 65 Expands Availability 65 Completes Non Brokered 65 Enters Exclusive 65 Receives Positive Rating 65 Panel Rejects 65 Spectrum Pharmaceuticals Announces 65 Shareholder Lawsuit 65 Files Annual Report